Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Although ponatinib is an FDA-approved TKI that directly targets T315I-Bcr-Abl leukemia, its association with cardiovascular toxicity is a significant concern in clinical therapy
Treatment targeting one aspect shows limited effects
Nutrition and Hydration Collagen synthesis requires adequate protein intake, particularly amino acids like glycine, proline, and hydroxyproline
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
US$ 20.59
US$ 27.02
US$ 27.31
US$ 28.65
US$ 29.45
